<table class="tg">
  <tr>
    <th class="tg-0lax">Disease</th>
    <th class="tg-0lax">Gene</th>
    <th class="tg-0lax">paper_link</th>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1" rowspan="5">COVID-19</td>
    <td class="tg-cly1">angiotensin I converting enzyme 2</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1128/jvi.00127-20">Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus</a></pre>
<pre><a href="http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.0014">[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].</a></pre>
<pre><a href="http://dx.doi.org/10.1016/j.bbrc.2020.02.071">Structure analysis of the receptor binding of 2019-nCoV</a></pre>
<pre><a href="http://dx.doi.org/10.1016/j.jinf.2020.02.013">Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV</a></pre>
<pre><a href="http://dx.doi.org/10.12688/f1000research.22211.2">Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</a></pre>
<pre><a href="http://dx.doi.org/10.1002/ddr.21656">Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics</a></pre>
<pre><a href="http://dx.doi.org/10.1126/science.abb2762">Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</a></pre>
<pre><a href="http://dx.doi.org/10.1016/j.cell.2020.02.052">SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</a></pre>
<pre><a href="http://dx.doi.org/10.1097/cm9.0000000000000797">Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model</a></pre>
<pre><a href="http://dx.doi.org/10.1002/ddr.21656">Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin B</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1038/s41422-020-0282-0">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</a></pre>
<pre><a href="http://dx.doi.org/10.1016/j.ijantimicag.2020.105923">Chloroquine for the 2019 novel coronavirus SARS-CoV-2</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin D</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1038/s41422-020-0282-0">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</a></pre>
<pre><a href="http://dx.doi.org/10.1016/j.ijantimicag.2020.105923">Chloroquine for the 2019 novel coronavirus SARS-CoV-2</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin K</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1002/minf.202000028">Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin L</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1038/s41422-020-0282-0">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</a></pre>
<pre><a href="http://dx.doi.org/10.1016/j.ijantimicag.2020.105923">Chloroquine for the 2019 novel coronavirus SARS-CoV-2</a></pre>
<pre><a href="http://dx.doi.org/10.5582/bst.2020.01047">Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</a></pre>
<pre><a href="http://dx.doi.org/10.2174/1568026620999200305145032">Effective Chemicals against Novel Coronavirus (COVID-19) in China</a></pre>
<pre><a href="http://dx.doi.org/10.5582/ddt.2020.01012">Discovering drugs to treat coronavirus disease 2019 (COVID-19)</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1" rowspan="9">SARS</td>
    <td class="tg-cly1">angiotensin I converting enzyme 2</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1128/jvi.00127-20">Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus</a></pre>
<pre><a href="http://dx.doi.org/10.1016/j.jinf.2020.02.013">Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">phosphofurin acidic cluster sorting protein 2</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1021/acsinfecdis.0c00052">Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin B</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1016/j.antiviral.2015.01.011">Protease inhibitors targeting coronavirus and filovirus entry</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin C</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1021/acsinfecdis.0c00052">Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin D</td>
    <td class="tg-cly1"><pre><a href="NONE">Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential</a></pre>
<pre><a href="http://dx.doi.org/10.1021/acsinfecdis.0c00052">Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin K</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1021/acsinfecdis.0c00052">Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin L</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1016/j.bbrc.2004.08.085">In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin La</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1021/acsinfecdis.0c00052">Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential</a></pre>
</td>
  </tr>
  <tr class="tg-cly1">
    <td class="tg-cly1">cathepsin S, ortholog2, tandem duplicate 1</td>
    <td class="tg-cly1"><pre><a href="http://dx.doi.org/10.1021/acsinfecdis.0c00052">Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential</a></pre>
</td>
  </tr>
</table>